Oxipit ChestLink and CXR Suite

Oxipit is a radiology AI company founded in 2017 in Lithuania by medicine and data science experts, and part of the Swedish medical IT company Sectra since 2026. It focuses on autonomous AI that removes normal studies from radiologists' worklists so specialists can concentrate on abnormal cases.

The CXR Suite combines ChestLink, which autonomously reports healthy chest X-rays, and ChestEye, which detects 75 findings such as pneumothorax, consolidation, effusion, edema and misplaced lines and tubes, and acts as a real-time quality safety net. Tiers range from notifications and triage to full autonomy for normal studies. In 2026 the company added CT Eye and MSK Eye for chest CT and musculoskeletal imaging. Customers are hospitals and imaging groups in Europe, Africa and Latin America.

• ChestLink: autonomous reporting of healthy chest X-rays with CE Class IIb certification.
• ChestEye: detection of 75 chest X-ray findings, including lines and tubes.
• Quality monitoring: real-time review that catches discrepancies in finalized reports.
• Tiered workflows: Basic, Standard, Advanced and Premium levels from alerts to full autonomy.
• Analytics dashboard: tracks AI-assisted triage and reporting performance.
• CT and MSK suites: CT Eye and MSK Eye extend the platform beyond chest X-ray.

Large check-up centers in Vietnam could use ChestEye to triage pre-employment and annual chest X-rays and focus radiologists on abnormal films. Hospital networks could run real-time quality review on finalized chest X-ray reports. Teleradiology providers could raise reading capacity without hiring more radiologists.

Automates up to 40% of chest X-ray reporting by autonomously handling healthy studies. Detects normal chest X-rays with 99.9% sensitivity according to the company, keeping safety high while cutting workload. Flags 75 findings and runs real-time quality review as a second check on human reports. Goes live in less than a week with minimal IT setup and scales from 5,000 to over 500,000 studies a year.

A large share of chest X-rays in screening and outpatient settings are normal, so autonomous reporting of normal studies is becoming a practical way to address radiologist shortages. Health check-up volumes in Vietnam and Southeast Asia include many routine chest X-rays, making normal-case automation relevant once local regulators accept autonomous AI.

Oxipit was founded in 2017 and is based in Vilnius, Lithuania. Sectra agreed to acquire the company in March 2026, and it has operated as part of Sectra since then. ChestEye received CE certification in 2019 and ChestLink holds CE Class IIb certification for autonomous use in Europe. Customers include German Medical Institute and Diagnostikum Group; partners include deepc and Newton's Tree.